Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sorrento Therapeutics Inc SRNE

Healthcare Biotechnology
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G... see more

Recent & Breaking News (GREY:SRNE)

Sorrento Announces Addition of COVI-STIX(TM) (Covid-19 Virus Rapid Antigen Detection Test) to the Official Mexican Government List of Emergency Use Approved Point of Care Rapid Antigen Tests

GlobeNewswire June 2, 2021

Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC(TM) in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome

GlobeNewswire May 20, 2021

Sorrento Reports Positive Initial Result in Dosing of First Enbrel-Non-Responding Rheumatoid Arthritis Patient With the Sofusa® Lymphatic Drug Delivery Device

GlobeNewswire May 19, 2021

Sorrento Receives FDA Clearance to Proceed With Phase 2 Study for Sti-3031, an Anti-Pd-L1 Antibody, for Advanced Urothelial Carcinoma

GlobeNewswire April 27, 2021

Sorrento Announces Positive Results of Phase 1b Study of COVI-MSC(TM) Treatment of ICU Covid-19 Patients, Achieving 100% (10 out 10) Discharge Rate

GlobeNewswire April 20, 2021

SORRENTO INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sorrento Therapeutics, Inc. - SRNE

Business Wire April 9, 2021

Scilex Holding, a Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for ZTlido® Label Expansion

GlobeNewswire April 9, 2021

Sorrento Enters Into Merger Agreement to Acquire Late-Stage Oncology Company ACEA Therapeutics

GlobeNewswire April 5, 2021

Sorrento Announces Updated Positive Results of Phase 1b Study of COVI-MSC(TM) for Treatment of ICU COVID-19 Patients

GlobeNewswire March 25, 2021

Sorrento Announces First Patient Treated in Phase IB AL Amyloidosis Trial with STI-6129, an Anti-CD38 Antibody-Drug Conjugate

GlobeNewswire March 18, 2021

Dr. Henry Ji to Participate in the CEO Roundtable during WuXi Healthcare Forum 2021 on March 17, 2021

GlobeNewswire March 17, 2021

SORRENTO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sorrento Therapeutics, Inc. - SRNE

PR Newswire March 12, 2021

Sorrento and Mount Sinai Health System Enter Into Exclusive License Agreement for Development of Potent Antibody Combinations Aimed at Neutralizing SARS-CoV-2 and the Emerging United Kingdom and South Africa Variants of COVID-19

GlobeNewswire March 9, 2021

Lee's Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Clearance to Start Phase 3 Trial as a First-line Treatment of Extensive-stage Small-Cell Lung Cancer

GlobeNewswire March 7, 2021

Dr. Henry Ji to Participate in the H.C. Wainwright Virtual GLOBAL LIFE SCIENCES CONFERENCE 2021 Investor Conference

GlobeNewswire March 5, 2021

Sorrento Receives US FDA Clearance to Proceed With Phase 1 Study for STI-2099 (Intranasal COVIDROPS) in Healthy Volunteers and Outpatient Treatment for Newly Diagnosed COVID-19 Positive Patients

GlobeNewswire March 2, 2021

Sorrento Receives FDA Clearance to Start Clinical Trial of Anti-CD47 Antibody, Discovered from Fully Human G-MAB Library, for Treatment of Multiple Malignancies

GlobeNewswire March 2, 2021

Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndrome

GlobeNewswire March 1, 2021

SORRENTO INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sorrento Therapeutics, Inc. - SRNE

Business Wire February 26, 2021

Lee's Pharmaceutical Announces Its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Breakthrough Therapy Designation in China for the Treatment of Recurrent or Metastatic Cervical Cancer

GlobeNewswire February 9, 2021